AMA Will Issue New CPT Code for AI Prostate Cancer Mapping Tool
The Current Procedural Terminology (CPT) Category III code for the Unfold AI prostate cancer mapping platform can be utilized by radiologists starting in July 2024.
The 2024 Current Procedural Terminology (CPT) codes from the American Medical Association (AMA) will include a new category III CPT code for the use of Unfold AI, an artificial intelligence (AI)-enabled mapping platform for prostate cancer imaging.
Unfold AI is reportedly the first AI-powered prostate cancer modality to receive a category III CPT code, according to Avenda Health, the manufacturer of Unfold AI.1
Avenda Health said the X237T CPT code, which goes into effect in July 2024, can be utilized for “Non-invasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report.”
"The new CPT code solidifies our position as a frontrunner in revolutionizing cancer care and our commitment to making our technology accessible to all patients,” noted Brittany Berry-Pusey, Ph.D., the COO and co-founder of Avenda Health.
In a retrospective study published earlier this year, researchers found that AI model margins with Unfold AI demonstrated a 96.9 percent sensitivity for diagnosing clinically significant prostate cancer (csPCa) in comparison to 37.4 percent for regions of interest (ROI) on conventional magnetic resonance imaging (MRI).2
References
1. Avenda Health. Avenda Health’s revolutionary AI mapping tool for prostate cancer achieves landmark category III CPT code designation. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/avenda-healths-revolutionary-ai-mapping-tool-for-prostate-cancer-achieves-landmark-category-iii-cpt-code-designation-301973699.html . Published November 1, 2023. Accessed November 1, 2023.
2. Hall J. Study says AI mapping more effective than MRI for assessing extent of prostate cancer. Diagnostic Imaging. Available at: https://www.diagnosticimaging.com/view/study-says-ai-mapping-more-effective-than-mri-for-assessing-extent-of-prostate-cancer . Published June 15, 2023. Accessed November 1, 2023.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
